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LIST OF ABBREVIATIONS 
 
 
ACS Acute coronary syndrome 
ADP Adenosine diphosphare 
ALI Acute limb ischaemia 
CABG Coronary artery bypass grafting  
PAD Peripheral artery disease 
PCI Percutanous coronary intervention 
PD Pharmacodynamic 
PK Pharmacokinetic 
PPCI Primary percutaneous coronary intervention 
PR Platelet reactivity 
RCT Randomised controlled trial 
SC Subcutaneous 
STEMI ST-elevation myocardial infarction 






Atherothrombosis of the coronary, cerebral or peripheral arteries may lead to acute coronary 
syndromes (ACS), stroke/transient ischaemic attack (TIA) and acute limb ischaemia (ALI) 
respectively, contributing to premature mortality and chronic morbidity. The central 
pathological process in these conditions is platelet activation, usually precipitated by 
rupture/erosion of an atherosclerotic plaque, with concurrent contact activation of coagulation 
and release of prothrombotic factors [1].  
 
Whilst platelet activation during thrombosis involves multiple pathways, the platelet P2Y12 
receptor (‘P2Y12’), activated by adenosine diphosphate (ADP) that is released from platelets in 
dense granules, plays a central role in amplifying the response to a range of agonists [1]. P2Y12 
therefore represents a powerful therapeutic target in arterial thrombosis. Several P2Y12 
antagonists have now been developed. Orally-administered agents include the thienopyridines 
clopidogrel and prasugrel that irreversibly inhibit P2Y12, and the cyclo-pentyl 
triazolopyrimidine ticagrelor, which reversibly binds to P2Y12 [2]. A parenterally-administered 
P2Y12 antagonist, cangrelor, is also available. Cangrelor is reversibly-binding with rapid onset 
and offset, but requires intravenous access and a maintenance infusion after an initial bolus 
reducing its practicability, as well as significant cost implications [3]. 
 
The effectiveness of P2Y12 antagonists in preventing cardiovascular events in patients with 
atherothrombosis is well established. Large randomised clinical trials (RCTs) have shown 
benefits of P2Y12 antagonists added to aspirin in ACS [2], or substituted for it in 
cerebrovascular disease and peripheral arterial disease (PAD) [4]. Furthermore, in ACS, 
particularly when managed by percutaneous coronary intervention (PCI), the more potent oral 
P2Y12 antagonists ticagrelor, in all ACS, and prasugrel, in the setting of ACS managed by PCI, 
offer clinical benefits over clopidogrel [2]. Similarly, intravenous cangrelor reduces ischaemic 
complications of PCI when compared to oral clopidogrel without increasing severe bleeding 
[3]. 
  
2. DEVELOPMENT AND PHARMACOLOGY OF SELATOGREL 
 
Selatogrel (4‐((R)‐2-|[6-((S)‐3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-
carbonyl]amino|-3-phosphonopropionyl)piperazine-1-carboxylic acid butyl ester), known 
earlier in development as ACT-246475, is a novel P2Y12 antagonist for subcutaneous (SC) 
administration. A selective, potent and reversibly-binding 2-phenyl-pyrimidine-4-carboxamide 
analogue, it shares a pyrimidine core with ticagrelor and other aspects of its structure with a 
family of molecules previously investigated as reversible P2Y12 antagonists (BX 048, BX 667; 
Berlex Biosciences) (Figure 1) [5]. 
 
In vitro studies characterised selatogrel’s basic pharmacology: using Chinese hamster ovary 
cells expressing P2Y12, the concentration required for 50% inhibition was 4.8 nmol/L, and 31 
nmol/L using light transmittance aggregometry of human platelet-rich plasma using 3 µmol/L 
ADP as an agonist [5]. It was determined that the drug was not metabolised by cytochrome 
P450 enzymes but was a substrate for the hepatic uptake transporters organic-anion-
transporting polypeptide 1B1 and 1B3 [6]. In animal studies, the drug led to significantly less 
bleeding whilst maintaining significant antithrombotic effect compared with clopidogrel or 
ticagrelor in an experimental rat model of arterial injury. The investigators concluded this 
suggested a wider therapeutic window than these two existing agents, although no human 
studies have been powered to assess this. [7, 8]. 
 
Following preclinical studies, several human phase I and II trials of selatogrel have now been 
performed (Table 1). In summary, a standard oral formulation of ACT-281959, a pro-drug of 
selatogrel, failed to achieve satisfactory reduction in platelet reactivity (PR), even at high doses. 
An aqueous-organic solution of ACT-281959 achieved a better response but had low 
palatability limiting dose escalation [9]. Subsequently, a SC-administered preparation of 
selatogrel was tested in healthy volunteers and its pharmacodynamics (PD) and 
pharmacokinetics (PK) determined [6, 10]. A dose-dependent potent effect on PR with rapid 
time to peak effect (30 minutes to 1 hour) and offset (significant by 8 hours, almost total by 24 
hours) was demonstrated, with good tolerance and safety. No plasma major metabolites were 
identified and elimination was largely faecal with a small urinary component. The investigators 
concluded that inhibitors or inducers of drug-metabolising enzymes are unlikely to affect 
selatogrel’s plasma profile, but could not rule out drug-drug interaction with agents affecting 
the hepatic uptake transporters organic-anion-transporting polypeptide (OATP) 1B1 and 1B3 
as well the efflux transporter multidrug resistance-associated protein 2 (MRP2), of which 
selatogrel is a substrate. This includes drugs such as cyclosporine, eltrombopag, lapatinib, 




Two phase 2 studies of SC selatogrel have now been reported. 345 patients were randomised 
in a 1:1:1 ratio to receive an SC injection of either selatogrel 8 mg, 16 mg or placebo [11]. 
Platelet function tests were performed before injection and at serial timepoints up to 24 hours 
after. Both doses of selatogrel rapidly and powerfully inhibited ADP-induced platelet 
activation by 30 minutes and with significant inhibition for at ³ 8 hours, reversing by 24 hours. 
Whether the injection site was the thigh or abdomen made no difference to the profile of effect. 
Significantly, in those patients already receiving maintenance therapy with an oral P2Y12 
antagonist, including clopidogrel or ticagrelor, selatogrel provided an additive effect.  No 
severe or serious adverse events occurred.  There was, however, an increased incidence of mild 
or moderate dyspnoea in those receiving selatogrel when compared to placebo, not seen in 
phase I studies. There was some evidence of this being a dose-dependent effect: 5% reported 
dyspnoea after 8 mg and 9% after 16 mg, compared to no reports after placebo.  Certain P2Y12 
antagonists (ticagrelor and cangrelor) are associated with increased rate of dyspnoea, sharing 
with selatogrel the property of reversible binding, suggested as a factor in this non-pathogenic 
phenomenon [3]. No other adverse effects appeared more common following drug rather than 
placebo, with the possible exception of dizziness, which occurred in 4% and 3% receiving 8 
mg and 16 mg respectively, and 1% receiving placebo; and injection site bruising (3% vs. 2% 
vs. 0%). No significant bleeding occurred in any participant and there were no changes in 
haemodynamic or electrocardiographic parameters. 
  
A study of 47 patients given selatogrel 8 or 16 mg SC in the early phase of ACS confirmed 
similar PD/PK findings [12]. 
 
3. EXPERT OPINION: POTENTIAL CLINICAL ROLES FOR SELATOGREL 
 
Selatogrel is currently neither commercially-available nor licensed for clinical use. Whilst only 
phase 2 trials have been conducted at present, the attractive prospect of a rapid-onset 
parenterally-administered potent and reversible P2Y12 antagonist raises the possibility of its 
use in a number of specific situations, especially, but not limited to, ACS (Figure 2). Outcome-
driven phase 3 data would, of course, be needed to make definitive recommendations but 
potential future roles can be speculated upon.  
 
3.1 Early P2Y12 inhibition in ACS 
Understanding the natural history of an ACS event can help to identify when P2Y12 inhibition 
might be beneficial. Coronary thrombosis with resulting distal ischaemia +/- infarction is a 
dynamic process, with thrombus being formed and broken down, the net effect determining the 
extent of vessel occlusion, a process that can take hours or even days to reach its peak [1]. Even 
in patients on pre-existing oral antiplatelet therapy, factors such as increased platelet turnover, 
compliance or reduced absorption may lead to reduced effect, and even small numbers of 
uninhibited platelets may initiate thrombosis. Whilst in high-risk groups there is evidence that 
long-term maintenance therapy with P2Y12 antagonists can help to prevent thrombotic events 
[2], this comes at the expense of bleeding risk, limiting the attractiveness of this strategy in the 
wider population. 
 
Hypothetically, delivering potent P2Y12 inhibition as early as possible during an ACS event 
may have clinical benefits, likely derived from a reduction in the impact of thrombosis on 
vessel occlusion and the most dangerous sequelae such as ST-elevation myocardial infarction 
(STEMI). However, early pre-hospital treatment with oral P2Y12 antagonists, for example to 
those with STEMI, has proved disappointing when compared to in-hospital dosing.  One factor 
potentially reducing benefits of pre-treatment is that absorption of oral P2Y12 antagonists in 
the proximal small intestine is significantly delayed by the presence of opioid drugs, commonly 
administered in ACS [13].  SC-administered selatogrel, with its rapid onset even during ACS, 
therefore represents an additional option to be investigated with the possibility of preventing 
the early thrombotic propagation and hence reducing haemodynamic impact within a coronary 
artery. The route of administration and the possibility of a pre-filled syringe is likely to be 
practical for pre-hospital administration by caregivers. Similarly, it is feasible that 
patients/carers could be trained to give selatogrel at the onset of a suspected ACS event, 
minimising delay, perhaps akin to the use of pre-filled adrenaline pen by patients at high-risk 
of anaphylaxis. Clearly this strategy would require robust investigation in the target population 
before it could be recommended. 
 
3.2 Use during primary percutaneous coronary intervention 
 
Similarly, whether oral P2Y12 antagonists should be given before or after primary PCI (PPCI) 
for STEMI remains debated. Providing cover with a parenteral antiplatelet agent, such as a 
glycoprotein IIb/IIIa inhibitor, may reduce the risk of acute ischaemic complications in those 
treated with opiates [13].  Use of selatogrel to achieve rapid P2Y12 inhibition during PPCI, 
circumventing reduced enteral absorption related to morphine or other factors, might 
hypothetically reduce the need for additional parenteral antiplatelet agents, e.g. glycoprotein 
IIb/IIIa inhibitors, with the attendant risk of increased bleeding.  
 
3.3 Peri-procedural bridging of P2Y12 inhibition 
The risk of bleeding during major operative procedures in patients receiving oral P2Y12 
antagonists is regarded as unacceptably high, hence these are normally withheld in all but the 
most emergent cases. This includes patients who are admitted to hospital with ACS and require 
urgent coronary artery bypass grafting (CABG) shortly after diagnosis, when their thrombotic 
risk remains high. The timing of discontinuation prior to procedures such as CABG may 
depend on the agent in question and is sometimes guided by platelet function testing [14]. The 
effect of ticagrelor, for example, begins to reduce from 1 day after discontinuation but it may 
take at least 72 hours for most patients to reach a level of PR deemed safe for surgery, longer 
if receiving clopidogrel or prasugrel [14]. This may lead to a period of vulnerability to further 
thrombosis, which is prolonged further in cases of inevitable delay. Speculatively, given the 
rapid onset and offset in effect of SC selatogrel, it may be possible to provide adequate P2Y12 
inhibition closer to the point of surgery than with oral drugs, similar to anticoagulation with 
SC low-molecular- weight heparin to cover a period of vitamin K antagonist discontinuation. 
Based on phase II data, it seems likely that P2Y12-mediated PR would fully recover in most 
patients by 24 hours after the last dose [15], thus allowing safe surgery sooner after 
discontinuation. Although the 8 and 16 mg doses tested in phase II showed relatively short 
periods of therapeutic effect (around 8 hours) meaning multiple injections per day may be 
needed, data from phase I trials suggests that using a higher dose e.g. 32 mg might prolong 
effect to around 12 hours per dose whilst still returning to near baseline by 24 hours after 
discontinuation, hence twice daily administration might be sufficient. Given kinetics may 
complicate multiple dosing regimens, prospective studies in this patient group would be needed 
to determine the appropriate doses and intervals, but the emergence of selatogrel is a promising 
development in this area.  
 
3.4 Use in patients with prolonged poor enteral absorption 
As well as circumventing poor absorption of oral P2Y12 antagonists in morphine-treated ACS 
patients, selatogrel may potentially find another theoretical niche in patients with longer 
periods of reduced enteral absorption. Whilst many patients who are ‘nil by mouth’ e.g. 
because of swallowing difficulties or reduced consciousness can receive oral P2Y12 antagonists 
via a nasogastric tube or as an orodispersible preparation of ticagrelor, some individuals present 
challenges when enteral absorption itself is disrupted, most notably those with prolonged 
periods of critical illness, but also those with chronic conditions such as short bowel syndrome. 
For specialist use, selatogrel may offer a feasible alternative in those rare cases where a reliable 
regimen of maintenance therapy with an enterally-active P2Y12 antagonist cannot be instigated. 
 
3.5 Use in other thrombotic conditions 
As well as ACS, dual antiplatelet therapy with aspirin and a P2Y12 antagonist may be of benefit 
in acute thrombotic stroke or high-risk TIA. For example, recent studies have suggested a 
reduction in ischaemic complications from acute stroke in those receiving aspirin and 
clopidogrel vs. aspirin alone, particularly early after the event [16]. Similarly, although a recent 
study of ticagrelor monotherapy vs. aspirin failed to show a statistically-significant difference 
in ischaemic events after acute stroke or high-risk TIA, a post-hoc analysis suggested those 
exposed to both drugs in the peri-infarct period may have improved outcomes compared to a 
single agent alone, a hypothesis now being tested prospectively in the THALES study 
(NCT03354429).  If P2Y12 inhibition is beneficial in acute thrombotic stroke, it is plausible 
that delivering this as soon as possible after onset of thrombosis may be optimal.  The rapid 
onset of selatogrel, combined with delays in administering oral medication to patients with 
acute stroke due to concerns regarding safe swallowing, means the novel agent may be a good 
candidate for further investigation in this setting. Contrary to ACS, it would be difficult, 
however, to envisage how a patient or pre-hospital caregiver could administer selatogrel in this 
situation given the need first to exclude intracranial haemorrhage. 
Similarly, in cases of ALI due to thrombosis, which may be treated by urgent angioplasty of 
the peripheral arteries, an oral P2Y12 antagonist e.g. clopidogrel is frequently given. 
Limitations of oral P2Y12 antagonists detailed above are potentially relevant in this situation 
too, hence selatogrel may have a role in improving the speed and reliability of antiplatelet 
therapy in acute manifestations of PAD. 
 
3.6 Limitations of current evidence 
Currently there are no human data to support preclinical work suggesting that selatogrel may 
have a safer profile compared to other P2Y12 antagonists and larger clinical studies are required 
to assess the safety of selatogrel, including its effect on bleeding rates. Indeed, it is expected 
that the effects of selatogrel on haemostasis in humans will be consistent with its profile as a 
P2Y12 antagonist, as initially suggested by numerical increase in injection-site bruising.  
Cangrelor is known to block the binding of thienopyridine active metabolites to P2Y12 [17] and 
further pharmacodynamic studies of selatogrel are required to investigate any potential 
negative interaction with clopidogrel and prasugrel in order to guide the switching from 
selatogrel to oral P2Y12 antagonists. 
 
4. CONCLUSIONS 
Selatogrel is a novel P2Y12 antagonist offering advantages of SC administration, rapid 
onset/offset and additive effect to maintenance oral therapy. An existing parenterally-
administered  P2Y12 antagonist, cangrelor, is available. It similarly provides rapid, potent and 
additive antiplatelet effect, and may improve clinical outcomes compared to oral agents in 
those undergoing PCI [3], but requires intravenous access so is less suited to pre-hospital or 
repeated administration. Achievement of rapid and reliable P2Y12 inhibition in ACS, ALI or 
acute thrombotic stroke is a logical goal and oral P2Y12 antagonists have limitations, as 
discussed.  It should be emphasised that no phase 3 trials have yet been performed, but there is 
clear rationale for investigating  the use of selatogrel to improve clinical outcomes in patients 
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Table 1 Human studies reported to date of the pharmacodynamics, pharmacokinetics and safety of selatogrel 
Study Study 
phase 
n Population Study treatment/design Key pharmacodynamic findings Key pharmacokinetic findings  Key safety findings 
Baldoni et 
al. 2014 [9] 
I 49 Non-smoking 
healthy males, 18 to 
45 years old, BMI 18 
to 
32 kg/m2. 
Part I (n=40): oral dose 
escalation of ACT-281959 (di-
ester pro-drug of selatogrel, 
doses up to 1000 mg) or placebo, 
dbRCT. 
Part II (n=9): crossover of single 
oral doses of selatogrel and two 
formulations of ACT-281959, 
open-label RCT. 
Part I: Although modest effects on PA and 
PRU were observed, all doses of oral ACT-
281959 tested failed to achieve 50% IPA. 
Part II: An aqueous-organic oral solution of 
70 mg ACT-281959 achieved mean >50% 
IPA, reverting to baseline by 12-24 hours. 
PD of other oral preparations of ACT-
281959 or selatogrel not assessed. 
Part I: Plasma selatogrel concentration 
peaked at 4 to 6 hours post-dose. None of 
the doses of ACT-281959 tested achieved 
mean peak selatogrel levels >IC50. 
Part II: Of the formulations tested, only the 
aqueous-organic oral solution of ACT-
281959 achieved peak selatogrel levels 
>IC50, peaking at 2 hours post-dose and 
~undetectable by 8 hours. 
No clinically relevant effects on 
laboratory parameters, ECG, 
physical examination, vital signs. 
Headache was most common AE, 
but occurred at similar rates 
between active drug and placebo. 
No bleeding events or dyspnoea. 
Juif et al 
2019 [10] 
I 48 Healthy male 
subjects aged 
between 19 and 45 
years, BMI 18 to 31 
kg/m2. 
Randomised to single SC dose of 
selatogrel 1, 2, 4, 8, 16 or 32 mg, 
or placebo, dbRCT. 
Dose-dependent reduction in PRU, lowest at 
30 minutes, duration of effect dependent on 
dose, reverted to baseline at all doses tested 
by around 24 hours. 
Dose-dependent plasma levels of 
selatogrel, peaking at 30 minutes post-
injection, undetectable by 8 to 12 hours. 
Plasma concentration of selatogrel 
correlated with inhibition of PA. Half-life 
of effect 1.3 to 9.2 hours depending on 
dose. 
No clinically relevant effects on 
laboratory parameters, ECG, 
physical examination, vital signs. 
AEs infrequent and not dose-
dependent. No bleeding events or 
dyspnoea. 
Ufer et al. 
2019 [6] 
I 6 Healthy males, 45 to 
63 years old, mean 
BMI 25.0 kg/m2. 
Single SC dose of 16 mg [14C]- 
radiolabelled selatogrel. 
Not assessed  Time to maximum plasma selatogrel ~45 
minutes, plasma half-life 4.7 hours. 
Geometric mean total recovery of [14C]-
radioactivity was 94.9% of which (92.5% 
in faeces, 2.4% in urine). No major 
metabolites isolated from plasma. M21 
(by gluconuridation) was most abundant 
metabolite in urine and A1 (by mono-
oxidation) in faeces.  
No serious adverse events or 
clinically relevant change of 
laboratory, vital sign or ECG data. 
2/6 had vasovagal presyncope 
after injection and 1/6 insomnia. 
No reported bleeding or dyspnoea.  
Storey et al. 
2019 [11] 
II 345 Patients receiving 
background oral 
antiplatelet therapy 
for stable CAD or 
MI > 3 months prior 
to enrolment. 
Single dose of selatogrel SC 8 mg 
vs 16 mg vs placebo, 1:1 
randomisation to thigh or 
abdomen injection site, dbRCT. 
8 mg and 16 mg achieved significant 
inhibition of ADP-induced PA and reduction 
in PRU achieved by 30 mins post-dose, 
sustained for at least 8 hours and returning to 
near baseline by 24 hours. 
Dose-dependent peak in plasma selatogrel 
at 30 minutes post-dose, falling in a 
logarithmic fashion to near-zero at 24 
hours. 
Dyspnoea in 5% of 8 mg group, 
9% of 16 mg group, 0% on 
placebo. Mild in all but one case 
(moderate). 
Injection/venepuncture site 




II 47 Males or post-
menopausal females, 
age 18 to 85 years, 
diagnosis of acute 
type 1 MI with 
symptom onset 
between 30 mins and 
6 hours before 
enrolment. 
Randomised 1:1 to a single SC 
dose of selatogrel 8 mg or 16 mg. 
Mean PRU below pre-defined response 
threshold after 15 minutes, 91% (8 mg) and 
95% (16 mg) were responders at 30 minutes. 
Effect persisted for at least 60 minutes. 
Plasma selatogrel peaked at 1 hour post-
dose, had reduced at 8 hours. 
Most frequent treatment-emergent 
AE = ventricular tachycardia (8 
mg: n=4, 16 mg: n=3). 1 case of 
mild dyspnoea (16 mg). 1 case of 
mild radial access bleeding (8 
mg). 
14C, carbon-14; AE, adverse event; BMI, body mass index; dbRCT, double-blinded randomised controlled trial; CAD, coronary artery disease; ECG, electrocardiogram; IC50, inhibitory concentration required for 50% 





Figure 1 (A) Molecular structure of the novel reversibly-binding P2Y12 antagonist selatogrel, shown for comparison alongside the oral P2Y12 
antagonist ticagrelor. (B) Illustrative figure demonstrating the temporal profile of a single subcutaneous dose of selatogrel’s effect on platelet 
reactivity, compared with an oral loading dose of ticagrelor with (solid line) and without (dotted line) concurrent morphine exposure. ADP, 




Figure 2 Potential clinical roles for selatogrel, a novel subcutaneous P2Y12 antagonist. ACS, acute coronary syndrome; PPCI, primary 
percutaneous coronary intervention. 
